New BUSINESS Research Available. Click Here to Access Article(s): https://t.co/E2692Yvzzf
RT @UMchear: New research on out-of-pocket spending on #orphandrugs in @JournalGIM from CHEAR faculty member Dr. @kaopingchua & Dr. @contir…
RT @UMchear: New research on out-of-pocket spending on #orphandrugs in @JournalGIM from CHEAR faculty member Dr. @kaopingchua & Dr. @contir…
RT @JournalGIM: On average, privately insured patients using orphan drugs spent $336 out-of-pocket on these #drugs in 2014. 1 in 7 spent >$…
On average, privately insured patients using orphan drugs spent $336 out-of-pocket on these #drugs in 2014. 1 in 7 spent >$500; 2 in 1000 spent >$7,500. High cost sharing could reduce access & treatment effectiveness @contirena1 @kaopingchua @UMi
Yes see our new analysis we have data to show a significant minority of pats have very large out of pocket payments https://t.co/DFQrfdYZNM. This is backwards of what we would expect based on insurance Econ 101
RT @UMchear: New research on out-of-pocket spending on #orphandrugs in @JournalGIM from CHEAR faculty member Dr. @kaopingchua & Dr. @contir…
RT @kaopingchua: Take-homes from our JGIM paper: Many are protected from high price of orphans. OOP =3% of total spending. But: 1) Many are…
New research on out-of-pocket spending on #orphandrugs in @JournalGIM from CHEAR faculty member Dr. @kaopingchua & Dr. @contirena1 of @ BUQuestrom. https://t.co/P2mKJlTWwH
RT @contirena1: privately insured patients using orphan drugs spent $336 out-of-pocket in 2014. 1 in 7 spent > $500; 2 in 1000 spent > $7,5…
RT @kaopingchua: Take-homes from our JGIM paper: Many are protected from high price of orphans. OOP =3% of total spending. But: 1) Many are…
Take-homes from our JGIM paper: Many are protected from high price of orphans. OOP =3% of total spending. But: 1) Many are not protected - distribution of OOP matters 2) We used MarketScan (large employer); coverage may be very generous 3) Can't observe n
RT @contirena1: privately insured patients using orphan drugs spent $336 out-of-pocket in 2014. 1 in 7 spent > $500; 2 in 1000 spent > $7,5…
RT @contirena1: privately insured patients using orphan drugs spent $336 out-of-pocket in 2014. 1 in 7 spent > $500; 2 in 1000 spent > $7,5…
RT @contirena1: privately insured patients using orphan drugs spent $336 out-of-pocket in 2014. 1 in 7 spent > $500; 2 in 1000 spent > $7,5…
RT @contirena1: privately insured patients using orphan drugs spent $336 out-of-pocket in 2014. 1 in 7 spent > $500; 2 in 1000 spent > $7,5…
RT @contirena1: privately insured patients using orphan drugs spent $336 out-of-pocket in 2014. 1 in 7 spent > $500; 2 in 1000 spent > $7,5…
RT @contirena1: privately insured patients using orphan drugs spent $336 out-of-pocket in 2014. 1 in 7 spent > $500; 2 in 1000 spent > $7,5…
privately insured patients using orphan drugs spent $336 out-of-pocket in 2014. 1 in 7 spent > $500; 2 in 1000 spent > $7,500. High cost sharing likely reduces access and treatment effectiveness. @kaopingchua @BU_HSM @DusetzinaS https://t.co/D
RT @JournalGIM: Out-of-pocket Spending on Orphan Drug Prescriptions Among Commercially Insured Adults in 2014 https://t.co/SzK5ojvlgJ
Out-of-pocket Spending on Orphan Drug Prescriptions Among Commercially Insured Adults in 2014 https://t.co/SzK5ojvlgJ